Monitor for a prospectus supplement if the company announces a drawdown on the shelf — any offering would dilute existing holders. The Phase III MAVERIC trial enrollment update is the next major catalyst; the shelf provides financing flexibility ahead of that readout but does not change near-term fundamentals.
Price Chart
Executive Summary
Cardiol Therapeutics filed a preliminary base shelf prospectus for up to US$150 million, enabling future offerings of common shares, debt, warrants, or units over 25 months. The filing includes expanded disclosure requested by OSC staff but does not restate any financials or change reported expenses, net loss, or cash position. No securities are being offered now, and the shelf does not obligate the company to conduct an offering — it is a routine capital-markets shelf registration for a late-stage biotech approaching a pivotal Phase III readout.
Key Facts
- Filed preliminary short-form base shelf prospectus for up to US$150 million aggregate offering price.
- No securities are being offered in connection with this announcement; no obligation to undertake an offering.
- Additional disclosure added at OSC staff request — no financial statements restated, no change to R&D, G&A, net loss, cash flows, or financial position.
- Shelf will be effective for 25 months once final prospectus receipt is issued.
- Phase III MAVERIC trial in recurrent pericarditis approaching target enrollment; Phase II ARCHER data in acute myocarditis positive; CRD-38 advancing toward first-in-human development.
Financial Impact
Shelf registration of up to US$150 million in aggregate offering price; no current offering or pricing terms disclosed.
Risk Factors
- Future offering under the shelf could dilute existing shareholders.
- Phase III MAVERIC trial may fail to meet endpoints, impairing the value proposition for any future capital raise.
- OSC review and expanded disclosure may signal heightened regulatory scrutiny of prior disclosures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000875 |
| Document: cardiol6k.htm | 0001279569-26-000875 |
| Document: 0001279569-26-000875-index-headers.html | 0001279569-26-000875 |
| Document: 0001279569-26-000875-index.html | 0001279569-26-000875 |
| Document: 0001279569-26-000875.txt | 0001279569-26-000875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.12 (−41.05%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.12 (−50.98%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.12 (−16.42%) |
Jul 14, 2026 14w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.12 (−2.61%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.12 (+12.90%) |
May 26, 2026 21w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.12 (−13.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers